'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing.

'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Abstract Text:

Hepatocyte nuclear factor-1alpha (HNF-1alpha) maturity onset diabetes of the young (MODY) is the commonest cause of monogenic diabetes but is frequently misdiagnosed as type 1 diabetes. The availability of genetic testing in MODY has improved diagnosis. Sulphonylurea sensitivity in HNF-1alpha patients means that those on insulin from diagnosis can transfer to sulphonylureas and may improve glycaemic control. To gain insight into the implications for patients of stopping insulin, in-depth interviews were conducted with eight HNF-1alpha patients transferred to sulphonylureas after a median of 20 years on insulin. Thematic content analysis highlighted four key themes: Fear, anxiety and excitement regarding stopping insulin, particularly among those who had been on insulin for many years or had never omitted insulin in the past. Improved lifestyle and self image accompanied by feelings of relief and 'increased normality'. Reflections on their time on insulin, including feelings of annoyance, particularly when the need for insulin treatment had been questioned at diagnosis. Difficulty 'letting go' of insulin treatment--some patients found it hard to believe that they no longer required injections as this conflicted with messages previously received from healthcare professionals. Transferring from insulin to sulphonylureas had a positive impact on lifestyle but support was needed for patients to adjust, many having grown up with the belief they would be on insulin for life.

'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Publishing Authors By Initials

For similar therapeutics: patient care: withholding treatment research abstracts see: therapeutics: patient care: withholding treatment research

PUBMED ID PMID:

MEDLINE DATE: 2004 Mar-Apr

'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Clinical medicine (London, England)

VOLUME: 4

Page Numbers: 144-7

Journal Abbreviation:

ISSN: 1470-2118

DAY: 14

MONTH: 05

YEAR: 2008

'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101092853

'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Keywords Mesh Terms:

KEYWORDS: Withholding Treatment

MESH TERMS: genetics

Chemical & Substance for Abstract: 'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Information

Substance Name: Hepatocyte Nuclear Factor 1

Registry Number: 126548-29-6

Grant and Affiliation Information for 'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing.

AFFILIATION: Department of Diabetes and Vascular Medicine, Peninsula Medical School, Exeter, Devon. M.H.Shepherd@exeter.ac.uk

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing Related Publications

• 'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing.
• A severe clinical phenotype results from the co-inheritance of type 2 susceptibility genes and a hepatocyte nuclear factor-1alpha mutation.
• Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young.
• Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers.
• Blood transfusions and the Rh factor.
• Can molecular genetics help in the clinic?
• Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation.
• Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes.
• Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1alpha and -1beta mutations.
• Diagnosis of maturity-onset diabetes of the young in the pediatric diabetes clinic.
• Different genes, different diabetes: lessons from maturity-onset diabetes of the young.
• Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.
• Genetics and type 2 diabetes in youth.
• Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics.
• Identifying hepatic nuclear factor 1alpha mutations in children and young adults with a clinical diagnosis of type 1 diabetes.
• Impaired maximum microvascular hyperaemia in patients with MODY 3 (hepatocyte nuclear factor-1alpha gene mutations).
• Intrauterine hyperglycemia is associated with an earlier diagnosis of diabetes in HNF-1alpha gene mutation carriers.
• Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes.
• Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity.
• Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization.
• Mutations in hepatocyte nuclear factor 1beta are not a common cause of maturity-onset diabetes of the young in the U.K.
• Mutations in the glucokinase gene of the fetus result in reduced placental weight.
• No evidence for linkage at candidate type 2 diabetes susceptibility loci on chromosomes 12 and 20 in United Kingdom Caucasians.
• Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young.
• Proposed mechanism for a novel insertion/deletion frameshift mutation (I414G415ATCG-->CCA) in the hepatocyte nuclear factor 1 alpha (HNF-1 alpha) gene which causes maturity-onset diabetes of the young (MODY).
• Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes.
• Serum amino acids in patients with mutations in the hepatocyte nuclear factor-1 alpha gene.
• The generalized aminoaciduria seen in patients with hepatocyte nuclear factor-1alpha mutations is a feature of all patients with diabetes and is associated with glucosuria.
• beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors.
• beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations.